Cantabio Pharmaceuticals, Inc.
CTBO
Other OTC1.01
USD
- -
- -
ISIN
US13808X2036
CUSIP
13808X203
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
-95.96
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Gergely Toth
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2225 East Bayshore Road Palo Alto CA United States of America 94303
- IPO Date
- Nov 16, 2015
- Website
- cantabio.com
- Similar Companies
- Business
- Cantabio Pharmaceuticals, Inc. operates as a preclinical-stage biotechnology company focused on the discovery and development of novel therapeutics and diagnostics primarily targeting neurodegenerative and metabolic diseases. The company’s core products and services include pharmacological chaperones and protein delivery-based therapeutics aimed at addressing underlying biochemical stress mechanisms such as protein aggregation, oxidative stress, and glyoxal stress. Its drug pipeline features small molecule drugs, fusion proteins, and radiopharmaceuticals targeting diseases including Parkinson’s disease, Alzheimer’s disease, and diabetic kidney disease. Key drug candidates include CB-3 and CB-101 for Parkinson’s disease, CB-301 targeting Alzheimer’s disease, and CB-201 for diabetes management. Cantabio Pharmaceuticals operates primarily in the United States but engages in research collaborations internationally. The company was founded in 2015 and is headquartered in San Mateo, California. It has formed partnerships with major research institutions, including a drug discovery agreement with NovAliX for Alzheimer's disease therapy development. A notable recent corporate development is the completion of a reverse merger with Gardedam Therapeutics, which expanded Cantabio’s operational capabilities. Additionally, Cantabio secured a significant grant from The Michael J. Fox Foundation for Parkinson’s Research to advance the development of novel therapeutics. These strategic collaborations and funding agreements support Cantabio’s growth in advancing preclinical-stage drug candidates toward clinical trials. Cantabio Pharmaceuticals’ business segments encompass therapeutic drug discovery, preclinical development, and licensing opportunities. The company aims its products and services at pharmaceutical partners, research institutions, and ultimately patients afflicted with neurodegenerative and metabolic disorders. Its continued focus on innovative mechanisms such as protein folding modulation and chaperone enhancement situates Cantabio at the cutting edge of biomedical research aimed at disease-modifying treatments. The company’s recent major changes include its merger with Gardedam Therapeutics, new drug discovery partnerships, and funding achievements that enhance its pipeline development and financial foundation. These moves reflect Cantabio’s strategic intent to accelerate product development and broaden its therapeutic reach in the competitive biotechnology industry. Overall, Cantabio Pharmaceuticals maintains a comprehensive portfolio of early-stage drug candidates with a specialized focus on neurological and metabolic diseases, leveraging strategic collaborations and funding to advance its clinical pipeline from discovery into translational development.